The accurate selection of the recipient is a crucial aspect in the field of lung transplantation (LTX), especially if patients were previously affected by oncological disease. The aim of this bicentric retrospective study was to evaluate short- and long-term outcomes in patients with previous oncological disease or unknown neoplasia found on native lungs submitted to LTX, compared to a control group. A total of 433 patients were included in the analysis, 31 with malignancies (Group 1) and 402 without neoplastic disease (Group 2). The two groups were compared in terms of short- and long-term outcomes. Patients in Group 1 were older (median age 58 years vs. 50 years,p= 0.039) and mostly affected by idiopathic pulmonary fibrosis (55% vs. 40%p= 0.002). Even though in Group 1 a lower rate of late post-operative complications was found (23% vs. 45%,p= 0.018), the median overall survival (OS) was lower compared to the control group (10 months vs. 29 months,p= 0.015). LTX represents a viable therapeutic option for patients with end-stage lung disease and a history of neoplastic disease. However, every case should be carefully debated in a multidisciplinary setting, considering oncological (histology, stage, and proper disease free-interval) and clinical factors (patient’s age and comorbidities). A scrupulous post-transplant follow-up is especially mandatory in those cases.
在肺移植领域，准确选择受者至关重要，尤其对于既往患有肿瘤性疾病的患者。这项双中心回顾性研究旨在评估既往有肿瘤病史或在移植前自体肺中发现未知肿瘤的肺移植患者，与对照组相比的短期及长期预后。研究共纳入433例患者，其中31例患有恶性肿瘤（第1组），402例无肿瘤性疾病（第2组）。两组患者在短期和长期预后方面进行比较。第1组患者年龄更大（中位年龄58岁 vs. 50岁，p=0.039），且主要受特发性肺纤维化影响（55% vs. 40%，p=0.002）。尽管第1组术后晚期并发症发生率较低（23% vs. 45%，p=0.018），但其总生存期中位数低于对照组（10个月 vs. 29个月，p=0.015）。对于终末期肺病且有肿瘤病史的患者，肺移植是一种可行的治疗选择。然而，每个病例都应在多学科背景下进行审慎评估，综合考虑肿瘤学因素（组织学类型、分期及适当的无病间期）和临床因素（患者年龄及合并症）。对于此类病例，严格的移植后随访尤为必要。
肿瘤(癌症)患者之家